Perillaldehyde: a promising antifungal agent to treat oropharyngeal candidiasis. - GreenMedInfo Summary
Perillaldehyde: a promising antifungal agent to treat oropharyngeal candidiasis.
Biochem Pharmacol. 2020 Aug 18:114201. Epub 2020 Aug 18. PMID: 32822688
Perillaldehyde (PAE), a natural monoterpenoid agent extracted from Perilla frutescence leaves, PAE has been reported to present various physiological capabilities, such as anti-inflammation, anti-oxidative and anti-fungal. In this study, we show that PAE exhibits strong antifungal activity against C. albicans. Candida albicans, a fungal pathogen with high incidence of antifungal resistance in clinical settings, is the major cause of oropharyngeal candidiasis (OPC). OPC is characterized by inflammatory immunological responses to fungal infections. Our in vitro results show PAE inhibited several virulence attributes of C. albicans including biofilm formation, yeast-to-hyphal transition and SAPs (secreted aspartic proteinases) gene expression. Using an experimental murine model of OPC, we found that PAE inhibited NLRP3 inflammasome assembly, reduced the excessive accumulation of ROS and prevented the p65 transfer in nuclear; processes all leading to reduced inflammation burden in the host. Together, this supports edible perilla or use PAE as a promising new agent to improve OPC.